SG11202010454PA - Genetically reprogrammed tregs expressing membrane-bound il-10 - Google Patents

Genetically reprogrammed tregs expressing membrane-bound il-10

Info

Publication number
SG11202010454PA
SG11202010454PA SG11202010454PA SG11202010454PA SG11202010454PA SG 11202010454P A SG11202010454P A SG 11202010454PA SG 11202010454P A SG11202010454P A SG 11202010454PA SG 11202010454P A SG11202010454P A SG 11202010454PA SG 11202010454P A SG11202010454P A SG 11202010454PA
Authority
SG
Singapore
Prior art keywords
bound
expressing membrane
genetically reprogrammed
tregs expressing
tregs
Prior art date
Application number
SG11202010454PA
Other languages
English (en)
Inventor
Gideon Gross
Hadas Weinstein-Marom
Amit Kroner
Original Assignee
Gavish Galilee Bio Appl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gavish Galilee Bio Appl Ltd filed Critical Gavish Galilee Bio Appl Ltd
Publication of SG11202010454PA publication Critical patent/SG11202010454PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
SG11202010454PA 2018-03-23 2019-03-22 Genetically reprogrammed tregs expressing membrane-bound il-10 SG11202010454PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647084P 2018-03-23 2018-03-23
PCT/IL2019/050324 WO2019180724A1 (en) 2018-03-23 2019-03-22 Genetically reprogrammed tregs expressing membrane-bound il-10

Publications (1)

Publication Number Publication Date
SG11202010454PA true SG11202010454PA (en) 2020-11-27

Family

ID=66448601

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010454PA SG11202010454PA (en) 2018-03-23 2019-03-22 Genetically reprogrammed tregs expressing membrane-bound il-10

Country Status (10)

Country Link
US (1) US20210347843A9 (ko)
EP (1) EP3768699A1 (ko)
JP (2) JP7404331B2 (ko)
KR (1) KR20210005602A (ko)
CN (1) CN112088164A (ko)
AU (1) AU2019240370B2 (ko)
CA (1) CA3094927A1 (ko)
IL (1) IL277541A (ko)
SG (1) SG11202010454PA (ko)
WO (1) WO2019180724A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020245329A1 (en) * 2019-03-26 2021-10-28 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed Tregs expressing CARs
EP4289859A1 (en) * 2022-06-10 2023-12-13 Medizinische Hochschule Hannover Fusion protein for maintenance of regulatory t-cells
WO2023237774A1 (en) * 2022-06-10 2023-12-14 Medizinische Hochschule Hannover Fusion protein for maintenance of regulatory t-cells
WO2024028881A1 (en) * 2022-08-03 2024-02-08 Migal Galilee Research Institute Ltd. Chimeric membrane-bound cytokines incorporating costimulatory elements for enhancing anti-inflammatory function

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089286A2 (en) * 2000-05-24 2001-11-29 Cel-Sci Corporation T cell binding ligand peptides, peptide constructs containing same and use thereof for treatment of immunological disorders
US20060003315A1 (en) * 2002-06-12 2006-01-05 Gavish-Galilee Bio Applications Ltd. Membrane-anchored beta2 microglobulin covalently linked to mhc class 1 peptide epitopes
WO2005010215A2 (en) * 2003-07-17 2005-02-03 Tolerrx, Inc. Methods for identifying tolerance modulatory compounds and uses therefor
DE10347710B4 (de) * 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
SI2126054T1 (sl) * 2007-01-31 2016-12-30 Yeda Research And Development Company Limited Preusmerjanje, genetsko spremenjene T regulatorne celice in njih uporaba v zatiranju avtoimunske in vnetne bolezni
ES2595364T3 (es) * 2008-10-07 2016-12-29 The Regents Of The University Of California Producción de proteínas NELL recombinantes
AU2013203561B2 (en) * 2009-05-15 2015-11-26 Irx Therapeutics, Inc. Vaccine immunotherapy
EP2457579A1 (en) * 2010-11-26 2012-05-30 Technische Universität Dresden Covalently linked interleukin -10
EP2691419B1 (en) * 2011-03-31 2016-11-09 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos and uses thereof
EP3842450A1 (en) * 2015-10-23 2021-06-30 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
WO2017123557A1 (en) * 2016-01-11 2017-07-20 Armo Biosciences, Inc. Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same
MY201207A (en) * 2016-04-01 2024-02-09 Amgen Inc Chimeric receptors to flt3 and methods of use thereof
WO2018005226A2 (en) * 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
CN107216395B (zh) * 2017-07-03 2018-07-20 上海科医联创生物科技有限公司 一种tm4sf1特异性嵌合抗原受体及其应用

Also Published As

Publication number Publication date
JP2021519107A (ja) 2021-08-10
US20210040169A1 (en) 2021-02-11
US20210347843A9 (en) 2021-11-11
CN112088164A (zh) 2020-12-15
WO2019180724A1 (en) 2019-09-26
IL277541A (en) 2020-11-30
KR20210005602A (ko) 2021-01-14
JP2024019533A (ja) 2024-02-09
EP3768699A1 (en) 2021-01-27
AU2019240370A1 (en) 2020-11-19
JP7404331B2 (ja) 2023-12-25
CA3094927A1 (en) 2019-09-26
AU2019240370B2 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
IL282413A (en) Tolyl is converted as a fungicide
IL288264A (en) Genetically engineered non-human animals that express human erythropoietin
SG10201902337QA (en) Prefabricated frame
IL277541A (en) Regulatory T cells expressing membrane-bound IL-10
EP3612210A4 (en) IMMUNE CELLS EXPRESSING MODIFIED ANTIGEN RECEPTORS
EP3811436A4 (en) BATTERY FRAME
EP3507373A4 (en) GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERAL PD-L1
IL286644A (en) Chimeric antigen receptors expressing genetically reprogrammed regulatory t cells
GB201820431D0 (en) Material conveyor
EP3612682C0 (en) LOADER FRAME
PL3840970T3 (pl) Otwierana konstrukcja
IL284105A (en) Pesticides in capsules
EP3872010A4 (en) ENCAPSULATED CONVEYOR
GB201806932D0 (en) Conveyor
GB201809276D0 (en) Electrochemical sensors
GB201708506D0 (en) Conveyor drive assembly
PT3659717T (pt) Sonotrodo
IL269167A (en) Conversion agent
EP3523224A4 (en) HYGIENIC CONVEYOR FRAME ASSEMBLY
EP3562652A4 (en) CONSTRUCTION MATERIALS CARRIERS
GB201820552D0 (en) Encapsulated sensors
GB2591920B (en) Mechanical linkage
GB201819188D0 (en) Foxp3 polypeptides
EP3668306A4 (en) GENETICALLY MODIFIED HAPLOIDISSATCHENKIA ORIENTALIS
GB201914153D0 (en) Foxp3 Polypeptides